{"schema_version":"secwatch.filing_event.v1","accession":"0001607062-22-000733","form_type":"8-K","ticker":"NUTX","cik":"0001479681","company_name":"Nutex Health Inc.","filed_at":"2022-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.801585+00:00","generated_at":"2026-06-21T14:03:47.147751+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Nutex Health reports Q3 net loss of $422.5M and $100M Lincoln Park equity facility","bullets":["Q3 net revenue $28.4M, down ~76% YoY, including $29M reduction in accounts receivable estimate.","Net loss attributable to Nutex $422.5M in Q3, driven by $408.5M non-cash goodwill impairment.","Adjusted EBITDA loss of $15.7M in Q3; positive $18.5M for nine months ended September 30, 2022.","Net cash from operations $46.1M for nine months; cash and equivalents $36.6M as of Sep 30.","Entered $100M common stock purchase agreement with Lincoln Park Capital over 36 months, no warrants."],"urls":{"canonical":"https://secwatch.observer/filing/0001607062-22-000733","json":"https://secwatch.observer/filing/0001607062-22-000733.json","markdown":"https://secwatch.observer/filing/0001607062-22-000733.md","text":"https://secwatch.observer/filing/0001607062-22-000733.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479681/000160706222000733/0001607062-22-000733-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479681/000160706222000733/nutx111422form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T14:03:47.147751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"256f39e63583bf773ff4b70e0f64b20039349fcc","claim":"Nutex Health Inc. reported Three months ended September 30, 2022 results: revenue $28.4 million, net income $(422.5) million.","evidence_excerpt":"Financial Highlights for the Three Months Ended September 30, 2022 (Unaudited): • Net revenue of $28.4 million. In the three months ended September 30, 2022, we reduced our estimate of the ultimate amounts of accounts receivable we will collect for prior periods. This change in estimate reduced revenue for the three months ended September 30, 2022 by approximately $29 million. • Net income attributable to Nutex Health of $(422.5) million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479681/000160706222000733/0001607062-22-000733-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Three months ended September 30, 2022"},{"label":"Revenue","value":"$28.4 million"},{"label":"Net income","value":"$(422.5) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"68e169704e6755d039af67a73e0636e257e24367","claim":"Nutex Health Inc. reported Nine months ended September 30, 2022 results: revenue $165.6 million, net income $(420.4) million.","evidence_excerpt":"Financial Highlights for the Nine Months Ended September 30, 2022 (Unaudited): • Net revenue of $165.6 million. • Net income attributable to Nutex Health of $(420.4) million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479681/000160706222000733/0001607062-22-000733-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Nine months ended September 30, 2022"},{"label":"Revenue","value":"$165.6 million"},{"label":"Net income","value":"$(420.4) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}